Clarity Pharmaceuticals Ltd. will begin early next year its pivotal phase III trial for its copper-based radiopharmaceutical, 64Cu-SAR-bisPSMA, for diagnosing prostate cancer in patients with biochemical recurrence following positive U.S. FDA feedback.
Tamra Sami is a science writer, editor, and publication manager with expertise in product development, particularly in Asia and emerging markets. As a staff writer for Bioworld co., Tamra focuses on covering a wide range of topics in the field of biotechnology, including advancements in precision health, clinical trial results, licensing deals, and emerging therapies.